Equities

Trinity Biotech PLC

Trinity Biotech PLC

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.27
  • Today's Change-0.01 / -0.78%
  • Shares traded123.51k
  • 1 Year change-63.19%
  • Beta1.2226
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast in USD

The one analyst offering a 12 month price target expects Trinity Biotech plc (ADR) share price to rise to 3.00 in the next year from the last price of 1.27.
High136.2%3.00
Med136.2%3.00
Low136.2%3.00

Earnings history & estimates in USD

On Aug 14, 2024, Trinity Biotech plc (ADR) reported 2nd quarter 2024 losses of -0.714 per share.
Average growth rate+9.00%
Trinity Biotech plc (ADR) reported annual 2022 losses of -6.08 per share on Mar 23, 2023.
Average growth rate-78.53%
More ▼

Revenue history & estimates in USD

Trinity Biotech plc had 2nd quarter 2024 revenues of 15.84m. This bettered the 15.75m estimate of the one analyst covering the company. This was 6.84% above the prior year's 2nd quarter results.
Average growth rate+2.20%
Trinity Biotech plc had revenues for the full year 2023 of 56.83m. This was 24.00% below the prior year's results.
Average growth rate-9.91%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.